Abstract
Beta-lactam- and in particular carbapenem-resistant Enterobacteriaceae represent a major public health threat. Despite strong variation of resistance across geographical settings, there is limited understanding of the underlying drivers.
To assess these drivers, we developed a transmission model of cephalosporin- and carbapenem-resistant Klebsiella pneumoniae. The model is parameterized using antibiotic consumption and demographic data from eleven European countries and fitted to the resistance rates for Klebsiella pneumoniae for these settings. The impact of potential drivers of resistance is then assessed in counterfactual analyses.
Based on reported consumption data, the model could simultaneously fit the prevalence of extended-spectrum beta-lactamase-producing and carbapenem-resistant Klebsiella pneumoniae (ESBL and CRK) across eleven European countries over eleven years. The fit could explain the large between-country variability of resistance in terms of consumption patterns and fitted differences in hospital transmission rates. Based on this fit, a counterfactual analysis found that reducing nosocomial transmission and antibiotic consumption in the hospital had the strongest impact on ESBL and CRK prevalence. Antibiotic consumption in the community also affected ESBL prevalence but its relative impact was weaker than nosocomial consumption. Finally, we used the model to estimate a moderate fitness cost of CRK and ESBL at the population level.
This work highlights the disproportionate role of antibiotic consumption in the hospital and of nosocomial transmission for resistance in gram-negative bacteria at a European level. This indicates that infection control and antibiotic stewardship measures should play a major role in limiting resistance even at the national or regional level.
Significance Statement As beta-lactam resistant gram-negative bacteria represent one of the most critical threats in the ongoing antibiotic resistance crisis, it is crucial to identify the underlying drivers and appropriate measures to curb their spread. By combining a transmission model with epidemiological data at a European level, we can explain the strong differences of extended-spectrum beta-lactamase-producing and carbapenem-resistant Klebsiella pneumonia across countries and their often-rapid temporal increase. We find that among potentially modifiable drivers, inpatient antibiotic consumption and nosocomial transmission rates have the strongest impact on resistance. This implies that infection control and antibiotic stewardship in hospitals are crucial for preventing antibiotic resistance in gram-negatives even beyond individual hospitals as they may affect resistance prevalence at the level of entire countries.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has been supported by the Swiss National Science Foundation (Grant no. BSSGI0_155851 to RDK).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All used data is publicly available.
https://gateway.euro.who.int/en/
https://www.ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/data-ecdc
https://www.ecdc.europa.eu/en/antimicrobial-consumption/surveillance-and-disease-data/database